Clinical Trial Update: MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma [Phase 1]

View source ↗

Summary

This is an update on a Phase 1 clinical trial of MCARH109 CAR-T cells for multiple myeloma; the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MCARH109

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING